Advertisement

International Journal of Hematology

, Volume 93, Issue 6, pp 779–781 | Cite as

CD20-negative Epstein–Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

  • Hideki Muramatsu
  • Yoshiyuki Takahashi
  • Yoshie Shimoyama
  • Sayoko Doisaki
  • Nobuhiro Nishio
  • Yoshinori Ito
  • Asahito Hama
  • Akira Shimada
  • Hiroshi Yagasaki
  • Masafumi Ito
  • Seiji KojimaEmail author
Case Report

Abstract

Epstein–Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

Keywords

Epstein–Barr virus Post-transplant lymphoproliferative disease CD20 Rituximab Aplastic anemia Unrelated bone marrow transplantation 

References

  1. 1.
    Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.CrossRefPubMedGoogle Scholar
  3. 3.
    Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502–5.PubMedGoogle Scholar
  6. 6.
    Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112–8.CrossRefPubMedGoogle Scholar
  7. 7.
    van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648–55.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Hideki Muramatsu
    • 1
  • Yoshiyuki Takahashi
    • 1
  • Yoshie Shimoyama
    • 2
  • Sayoko Doisaki
    • 1
  • Nobuhiro Nishio
    • 1
  • Yoshinori Ito
    • 1
  • Asahito Hama
    • 1
  • Akira Shimada
    • 1
  • Hiroshi Yagasaki
    • 1
  • Masafumi Ito
    • 3
  • Seiji Kojima
    • 1
    Email author
  1. 1.Department of PediatricsNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Pathology and Laboratory MedicineNagoya University HospitalAichiJapan
  3. 3.Department of PathologyJapanese Red Cross Nagoya First HospitalAichiJapan

Personalised recommendations